Algorithm at the heart of Moderna–Merck personalised cancer vaccine examined

A long-form investigation by STAT News examines the computational algorithm that determines which tumour-specific mutations are selected as targets in the personalised mRNA cancer vaccine co-developed by Moderna and Merck. The vaccine, known as mRNA-4157 / V940, has previously reported phase 3 success in melanoma and is now in broader oncology trials.

The piece raises questions about transparency in the neoantigen selection process: the algorithm that decides which of a patient's hundreds of somatic mutations will be encoded in a bespoke vaccine dose is proprietary, and independent researchers have limited visibility into its decision logic. STAT News notes that this opacity makes it difficult to determine whether clinical benefit derives primarily from the immunological design of the vaccine or from the algorithm's ability to prioritise immunogenic targets.

For the genetics and genomics research community, the story is notable because the entire pipeline — tumour sequencing, somatic variant calling, HLA typing, neoantigen prediction, and mRNA synthesis — is a translational application of population-scale genomic and computational methods. Researchers interested in variant effect prediction, tumour mutational burden, and personalised immunotherapy will find the methodological scrutiny particularly relevant.

The earlier phase 3 efficacy findings were reported in Genetic Current on 20 August 2026. Today's coverage focuses on the algorithm itself rather than the clinical outcome, representing additional analytical commentary rather than a new clinical result.